Methods of using adipose derived regenerative cells in the treatment of renal diseases and disorders
View Patent ↗Cells present in processed lipoaspirate tissue are used to treat patients, including patients with renal conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in processed lipoaspirate are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic renal benefit.
1. A method for treating a renal disorder associated with ischemia in a subject, comprising:
identifying a subject with impaired renal function; and
administering to the subject an amount of a concentrated population of adipose-derived regenerative cells comprising adipose-derived stem cells and endothelial progenitor cells sufficient to improve function of the kidney of said patient, wherein at least 0.1% of the concentrated population of adipose-derived cells are stem cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells.
2. The method of claim 1 , wherein the renal disorder associated with ischemia is identified by assessing serum creatinine levels.
3. The method of claim 1 , wherein the renal disorder associated with ischemia is identified by assessing blood urea nitrogen levels.
4. The method of claim 1 , wherein the renal disorder associated with ischemia is identified by assessing serum chemistry profiles.
5. The method of claim 1 , wherein the renal disorder associated with ischemia is identified by urinalysis.
6. The method of claim 1 , wherein the renal disorder associated with ischemia is identified by assessing glomerular filtration rate.
7. The method of claim 1 , wherein the subject is provided the concentrated population of adipose-derived regenerative cells within 12 hours after renal failure.
8. The method of claim 1 , wherein the subject has post-surgical traumatic injury.
9. The method of claim 1 , wherein the concentrated population of adipose-derived regenerative cells is not cultured before being provided to the patient.
10. The method of claim 1 , wherein the concentrated population of adipose-derived regenerative cells is autologous.
11. The method of claim 1 , wherein the renal disorder associated with ischemia comprises acute tubular necrosis.
12. The method of claim 1 , wherein the renal disorder associated with ischemia comprises atherosclerotic renal artery stenosis.
13. The method of claim 1 , wherein the administration comprises intravascular or intra-arterial administration.
14. The method of claim 1 , wherein the administration comprises administration to the subject's renal vasculature.
15. The method of claim 1 , wherein the concentrated population of adipose-derived regenerative cells is allogeneic.
16. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells further comprises an additive.
17. The method of claim 16 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, and an angiogenic factor.
18. The method of claim 16 , wherein the additive reduces the likelihood of adverse reaction on infusion of the concentrated population of adipose-derived regenerative cells into the subject.
19. The method of claim 1 , wherein said concentrated population of cells comprising adipose-derived stem cells is cryopreserved.